A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)

NCT01021527 · Completed

Last updated 2026-05-28

This study tested how the medication exenatide affects insulin production in healthy individuals during a controlled glucose infusion.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 12 people

Who can join Ages 18–45 · male only Healthy volunteers accepted.

Timeline Started 2008-02 · est. completion 2008-04

What this study is testing ClinicalTrials.gov NCT01021527 ↗

Description as written by the study sponsor.

A four-period study to evaluate if the grade glucose infusion procedure will be able to detect an increase in beta-cell glucose sensitivity from exenatide compared to no treatment in healthy subjects.

Treatments tested

Comparator: Treatment A Other

No Treatment
Comparator: Treatment B Drug

single dose administration of exenatide 5ug by subcutaneous injection
Comparator: Treatment C Drug

single dose administration of exenatide 10ug by subcutaneous injection
Comparator: graded glucose infusion Procedure

A stepwise graded infusion of glucose (20% dextrose \[D20\]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.

Main thing measured	beta-cell glucose sensitivity (slope of the relationship between insulin secretion rate and glucose)
Sponsor	Merck Sharp & Dohme LLC
Conditions studied	Healthy
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01021527 ↗